Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Eli Lilly and Co - Key Facts

Eli Lilly and Co - Key Employees

Eli Lilly and Co - Key Employee Biographies

Eli Lilly and Co - Major Products and Services

Eli Lilly and Co - History

Eli Lilly and Co - Company Statement

Eli Lilly and Co - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Eli Lilly and Co - Business Description

Business Segment: Animal Health

Overview

Performance

Business Segment: Human Pharmaceuticals

Overview

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Other Foreign Countries

Performance

Geographical Segment: United States

Performance

R&D Overview

Eli Lilly and Co - Corporate Strategy

Eli Lilly and Co - SWOT Analysis

SWOT Analysis - Overview

Eli Lilly and Co - Strengths

Eli Lilly and Co - Weaknesses

Eli Lilly and Co - Opportunities

Eli Lilly and Co - Threats

Eli Lilly and Co - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Eli Lilly and Co, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 28, 2019: Lilly and ImmuNext enter autoimmune disease research alliance

Mar 20, 2019: NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology

Mar 04, 2019: Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price

Feb 18, 2019: Lilly closes $8bn Loxo Oncology acquisition

Feb 15, 2019: Bayer gains full rights to TRK inhibitors Vitrakvi, LOXO-195 as Eli Lilly completes Loxo Oncology deal

Feb 15, 2019: Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

Feb 13, 2019: Drugs targeting metastatic cancers, opioid addiction are among additional specialty drugs available through AllianceRx Walgreens Prime

Feb 06, 2019: Lilly reports strong fourth-quarter and full-year 2018 financial results, lowers 2019 EPS guidance to reflect the pending acquisition of loxo oncology

Jan 31, 2019: Sanofi, Lilly and Novo face enquiry over high insulin prices in US

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Mar 28,2019 Lilly and ImmuNext enter autoimmune disease research alliance
Mar 20,2019 NCCN announces six quality improvement projects in Gastric Cancer care approved for collaboration with Lilly Oncology
Mar 04,2019 Eli Lilly to launch authorised Humalog generic in the US at 50-percent lower list price
Feb 18,2019 Lilly closes $8bn Loxo Oncology acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company